drugset
drugset / Trial / NCT05058118

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)

NCT05058118 ↗

Phase 1 Completed 54 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety,tolerability and pharmacokinetics of single intravenous doses of FL058 in healthy Chinese subjects.

Timeline

Start
2019-12-08
Primary completion
2020-06-03
Completion
2020-06-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject FL058 Small molecule 50 mg Intravenous
Subject FL058 Small molecule 250 mg Intravenous
Subject FL058 Small molecule 500 mg Intravenous
Subject FL058 Small molecule 1000 mg Intravenous
Subject FL058 Small molecule 1500 mg Intravenous
Subject FL058 Small molecule 2000 mg Intravenous

Indications

No indication recorded.